Direct and indirect targeting of MYC to treat acute myeloid leukemia
Open Access
- 9 May 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 76 (1), 35-46
- https://doi.org/10.1007/s00280-015-2766-z
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Small-Molecule Inhibition of BRDT for Male ContraceptionCell, 2012
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature, 2011
- Targeting MYC dependence in cancer by inhibiting BET bromodomainsProceedings of the National Academy of Sciences of the United States of America, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Reversible suppression of an essential gene in adult mice using transgenic RNA interferenceProceedings of the National Academy of Sciences, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinaseProceedings of the National Academy of Sciences, 2010
- c-Myc Regulates Transcriptional Pause ReleaseCell, 2010
- Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicinBiochemical Pharmacology, 2007